Diamond Biofund (6901.TW) Earnings Analysis

Diamond Biofund (6901.TW) next reports earnings on 2026-08-07, consensus EPS -1.08 TWD. It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E -15.21.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 6901.TW next report earnings?

Next earnings date2026-08-07
Consensus EPS estimate-1.08 TWD
Revenue estimaten/a

6901.TW earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-04-0.0172 TWDn/an/an/a
2025-11-10-0.17 TWDn/an/an/a
2025-06-30-0.52 TWDn/an/an/a
2024-12-31-0.89661 TWD0.44 TWD-303.8%Miss
2024-09-30-0.95 TWD0.38 TWD-350%Miss

Beat rate: 0/2 (0%) over reported quarters with consensus data.

6901.TW valuation and analyst view

Trailing P/E-15.21
Trailing EPS-1.12532 TWD
Price / book1.65
Dividend yield0.00%
Market cap14.93B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Diamond Biofund (6901.TW)'s next earnings date?

Diamond Biofund is next scheduled to report on 2026-08-07, with a consensus EPS estimate of -1.08 TWD.

Did 6901.TW beat earnings last quarter?

Consensus estimate data was not available for 6901.TW's 2026-03-04 report.

What is 6901.TW's earnings track record?

Over the last 2 reported quarters with consensus data, 6901.TW beat estimates 0 times (0%).

What is 6901.TW's current P/E ratio and EPS?

6901.TW trades at a trailing P/E of -15.21 on trailing EPS of -1.1253171948948626 TWD.

What do analysts rate 6901.TW?

6901.TW has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.